DaVita (NYSE:DVA) Stock Rating Upgraded by Wall Street Zen

DaVita (NYSE:DVA) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

A number of other research analysts also recently issued reports on the company. Truist Financial reduced their price target on DaVita from $250.00 to $215.00 and set a “hold” rating on the stock in a report on Friday, August 7th. Zacks Research cut DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. TD Cowen upgraded DaVita from a “hold” rating to a “buy” rating and increased their price objective for the stock from $201.00 to $220.00 in a report on Friday, August 7th. Oppenheimer set a $220.00 price objective on DaVita in a research report on Friday, August 7th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $265.00 target price on shares of DaVita in a research note on Wednesday, August 5th. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $233.43.

DaVita Stock Down 0.1%

Shares of DaVita stock opened at $187.16 on Friday. The company’s fifty day simple moving average is $180.47 and its two-hundred day simple moving average is $190.83. DaVita has a 12-month low of $101.00 and a 12-month high of $247.49. The firm has a market cap of $11.94 billion, a PE ratio of 15.32, a price-to-earnings-growth ratio of 0.49 and a beta of 0.80.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, beating the consensus estimate of $3.88 by $0.14. The firm had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.95 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, sell-side analysts expect that DaVita will post 14.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On DaVita

A number of large investors have recently modified their holdings of the stock. Value Investment Professionals LLC lifted its holdings in DaVita by 2.0% in the second quarter. Value Investment Professionals LLC now owns 2,501 shares of the company’s stock worth $556,000 after buying an additional 50 shares during the period. Kesler Norman & Wride LLC boosted its position in DaVita by 0.8% during the 1st quarter. Kesler Norman & Wride LLC now owns 6,816 shares of the company’s stock valued at $1,048,000 after acquiring an additional 55 shares in the last quarter. State of Alaska Department of Revenue grew its holdings in shares of DaVita by 1.9% during the 3rd quarter. State of Alaska Department of Revenue now owns 3,206 shares of the company’s stock worth $560,000 after acquiring an additional 60 shares during the period. Northwestern Mutual Wealth Management Co. grew its holdings in shares of DaVita by 4.1% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,915 shares of the company’s stock worth $426,000 after acquiring an additional 76 shares during the period. Finally, CoreCap Advisors LLC raised its position in shares of DaVita by 161.7% in the 3rd quarter. CoreCap Advisors LLC now owns 157 shares of the company’s stock worth $27,000 after acquiring an additional 97 shares in the last quarter. Institutional investors own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc is a healthcare company focused on kidney care and renal disease management. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with end-stage kidney disease, including hemodialysis and peritoneal dialysis, as well as home dialysis support.

The company also operates hospital-based dialysis programs and offers clinical, administrative and care-coordination services intended to support patients across the kidney-care journey.